Impact of Species and Tissue Differences on In Vitro Glucuronidation of Diclofenac
Open Access
- 12 December 2024
- Vol. 29 (24) , 5867
Abstract
Background: The aim of this study is to determine the impact of species and tissue differences on the glucuronidation of diclofenac in vitro. Method: Microsomes from different species (rat, monkey, mouse, dog, and human) and rat and human tissues (liver, intestine, and kidney) were used to assess the rate of glucuronidation reaction of diclofenac. The metabolites were quantified using ultra high-performance liquid chromatography (UHPLC) and fitted into a Michaelis–Menten model to determine the metabolic kinetic parameters. Results: The results showed higher rates of metabolism in the liver as compared to that of the intestine and kidney by both human and rat tissues microsomes. There were also differences in the rate of metabolism in the liver across the tested species, with mouse liver microsome having the highest maximum reaction rate (Vmax) at 7.22 nmol/min/mg followed by human liver microsome at 6.66 ± 0.33 nmol/min/mg, dog liver microsome at 5.05 ± 0.42 nmol/min/mg, monkey liver microsome at 3.88 ± 0.15 nmol/min/mg, and rat liver microsome at 0.83 ± 0.04 nmol/min/mg. Conclusions: This study demonstrated that the liver is the major organ for the glucuronidation of diclofenac. In addition, glucuronidation of diclofenac was different across the tested species; therefore, the influence of species should be taken into consideration in the pharmacological, pharmaceutical, and toxicological study of diclofenac.Keywords
Funding Information
- National Institute of General Medical Sciences (R16 GM149425, RP240430, U54MD007605)
- Cancer Prevention and Research Institute of Texas (R16 GM149425, RP240430, U54MD007605)
- National Institute of Minority Health and Health Disparity (R16 GM149425, RP240430, U54MD007605)
This publication has 30 references indexed in Scilit:
- Diclofenac, a NSAID, delays fracture healing in aged miceExperimental Gerontology, 2023
- Intestinal Metabolism of Diclofenac by Polymorphic UGT2B17 Correlates with its Highly Variable Pharmacokinetics and Safety across PopulationsClinical Pharmacology & Therapeutics, 2023
- CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent MechanismAdvanced Science, 2022
- Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humansDrug Metabolism and Pharmacokinetics, 2018
- Toxicological role of an acyl glucuronide metabolite in diclofenac‐induced acute liver injury in miceJournal of Applied Toxicology, 2016
- Tissue and species differences in the glucuronidation of glabridin with UDP-glucuronosyltransferasesChemico-Biological Interactions, 2015
- Disposition Kinetics of Diclofenac in the Dual Perfused Rat LiverJournal of Pharmaceutical Sciences, 2013
- Comparison of thromboembolic events in patients treated with Celecoxib, a Cyclooxygenase-2 specific inhibitor, versus Ibuprofen or DiclofenacThe American Journal of Cardiology, 2002
- Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathwaysBiochemical Pharmacology, 1999
- Pharmacokinetics and bioavailability of diclofenac in the ratJournal of Pharmacokinetics and Biopharmaceutics, 1991